Just wanted to throw something into the discussion for comparative purposes.
Karuna's drug treats Schizophrenia - and possibly other conditions - but Schizophrenia is the main focus from what I gather. The NIMH (National Institute for Mental Health) in the USA estimates that "Across studies that use household-based survey samples, clinical diagnostic interviews, and medical records, estimates of the prevalence of schizophrenia and related psychotic disorders in the U.S. range between 0.25% and 0.64%".
If you do the numbers in the USA, based on a population size of 331 million, it looks like between 827,000 - 2.1 million people suffer from the condition.
Now compare that with Autism, which in my view, is a genuine option on the table for any acquirer of 2591 or Neuren altogether, should the 3 remaining trials be positive - which I am extremely confident they will be. The CDC estimates that Autism impacts 2.21% of adults and 2.8% of children. Even if you went the lower figure, and then rounded down to just 2%, and just applied that to the population at large, you would have a patient population of approximately 6.62 million people. There is still plenty of meat on the bone, considering I rounded down the overall prevalence and did not factor in the significant increase in prevalence over time. In 2000, 1 in 150 children were diagnosed with Autism, compared to 1 in 36 today, according to the CDC.
If Karuna was worth $14b US, to treat a patient population of 2.1 million people at the top end of the range, how much would a company be worth who had a treatment for a condition with a population size more than 3 times the size of that associated with Schizophrenia.
A similar deal to Karuna would value Neuren at circa $160 per share if my maths is correct. Using the same methodology, a deal that valued the larger market size for Autism at 3 times that of Schizophrenia, would value Neuren at $480 per share - without taking into consideration any of the current conditions subject to trials or the ongoing revenue from Trofinetide.
I know that this is not how the world works but I think its an instructive way to consider the potential in the drug we are developing.
- Forums
- ASX - By Stock
- NEU
- Bristol Myers to acquire Karuna for $14Billion
Bristol Myers to acquire Karuna for $14Billion, page-23
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$19.61 |
Change
0.300(1.55%) |
Mkt cap ! $2.509B |
Open | High | Low | Value | Volume |
$19.39 | $19.98 | $19.38 | $4.483M | 227.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 177 | $19.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.61 | 32 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 65 | 19.640 |
2 | 215 | 19.630 |
2 | 148 | 19.620 |
2 | 229 | 19.610 |
3 | 363 | 19.600 |
Price($) | Vol. | No. |
---|---|---|
19.650 | 145 | 3 |
19.660 | 188 | 8 |
19.670 | 448 | 8 |
19.680 | 500 | 5 |
19.690 | 635 | 7 |
Last trade - 13.54pm 14/06/2024 (20 minute delay) ? |
|
|||||
Last
$19.56 |
  |
Change
0.300 ( 0.88 %) |
|||
Open | High | Low | Volume | ||
$19.41 | $19.97 | $19.39 | 46421 | ||
Last updated 14.12pm 14/06/2024 ? |
Featured News
NEU (ASX) Chart |